CKS1B在肺癌耐药机制中的研究进展  

RESEARCH PROGRESS OF CKS1B IN THE MECHANISM OF DRUG RESISTANCE IN LUNG CANCER

作　　者：滕传辉 王宇飞[2] 郭占林[2] TENG Chuanhui;WANG Yufei;GUO Zhanlin(First School of Clinical Medicine,Inner Mongolia Medical University,Hohhot 010059,China;Department of Thorocic Surgery,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China)

机构地区：[1]内蒙古医科大学第一临床医学院,内蒙古呼和浩特010059 [2]内蒙古医科大学附属医院胸外科,内蒙古呼和浩特010050

出　　处：《内蒙古医科大学学报》2024年第1期96-100,共5页Journal of Inner Mongolia Medical University

基　　金：国家自然科学基金项目(81760528)。

摘　　要：肺癌是全球常见的恶性肿瘤之一,极大地威胁着人们的健康和生命。化疗仍然是大部分肺癌晚期患者的主要治疗方法,但是耐药是治疗失败的主要原因,如何克服肿瘤耐药是今后研究的方向,CDC28蛋白激酶调节亚基1B(CKS1B)是CKS家族的一员,可与CDK催化亚基结合,调节细胞周期功能。近年来研究发现,CKS1B在多种肿瘤中是一种促癌因子,可促进肿瘤的发生,并且与患者预后不良密切相关。本文综述了CKS1B对肺癌细胞的影响机制及作为治疗靶点的最新研究。Lung cancer is one of common malignant tumors in the world,which is a great threat to people's health and life.Chemotherapy is still the main treatment method for most advanced patients,but drug resistance is the main reason for treatment failure.How to overcome tumor drug resistance is the direction of future research.CDC28 protein kinase regulatory subunit 1B(CKS1B),a member of the CKS family,can combine with CDK catalytic subunit to regulate cell cycle function.In re-cent years,studies have found that CKS1B is a cancer-promoting factor in a variety of tumors,which can promote the occur-rence of tumors and is closely related to poor prognosis of patients.In this review,the mechanism of CKS1B on lung cancer cells and its therapeutic target were reviewed.

关 键 词：CKS1B 肺癌 耐药 预后 

分 类 号：R734.2[医药卫生—肿瘤]